Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia

27 Jun 2015

Abstract excerpt

PR-104, a phosphate ester of the nitrogen mustard prodrug PR-104A, has shown evidence of efficacy in adult leukemia clinical trials. Originally designed to target hypoxic cells, PR-104A is independently activated by aldo-keto-reductase 1C3 (AKR1C3). The aim of this study was to test whether AKR1C3 is a predictive biomarker of in vivo PR-104 sensitivity. In a panel of 7 patient-derived pediatric acute...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Childhood Cancer Survivors' Quality of Life
Share to Immune Cell Function and Interaction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26116659
DOI: 10.1182/blood-2014-12-618900

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemiaPMID 26116659Read ↗

AKR1C3 Expression in T and B Acute Lymphoblastic Leukemia/Lymphoma for Clinical Use as a BiomarkerSemantic proximity Read ↗

AKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarkerSemantic proximity Read ↗

AKR1C enzymes sustain therapy resistance in paediatric T-ALLSemantic proximity Read ↗

Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemiaSemantic proximity Read ↗

BRD4 PROTAC Degrader ARV-825 Inhibits T-Cell Acute Lymphoblastic Leukemia by Targeting 'Undruggable' Myc-pathway GenesSemantic proximity Read ↗

The orally bioavailable GSPT1/2 degrader SJ6986 exhibits in vivo efficacy in acute lymphoblastic leukemiaSemantic proximity Read ↗

YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathwaySemantic proximity Read ↗

Cell and Molecular Determinants of <i>In Vivo</i> Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia XenograftsSemantic proximity Read ↗

Alternative Lengthening of Telomeres in Cancer Confers a Vulnerability to Reactivation of p53 FunctionSemantic proximity Read ↗

The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human NeuroblastomaSemantic proximity Read ↗

Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.